NUNZIUM

On Wednesday the experimental drug “lecanemab”, developed by Eisai (Japan) and Biogen (USA), has been declared efficient as a result of a large phase 3 clinical study involving 1795 patients with early Alzheimer’s disease. With high statistical significance, lecanemab has shown a reduction in clinical decline in patients. It has been shown that the drug slowed the progress of the disease by 27% compared to the placebo. Toxic plaques made of “amyloid-beta” proteins are considered the probable cause of Alzheimer’s disease. The drug reduced the number of toxic plaques in the brain and slowed the decline in memory and ability to perform daily tasks. Lecanemab has been the first one able to successfully slow cognitive decline in Alzheimer’s patients. This is a great achievement for science and medicine, which now offer hope for patients and their families desperate for effective treatment. The multinational pharmacology company Roche, together with Genentech and the Swiss laboratory AC Immune is developing a second drug based on the same principle, which hopefully will even reinforce future treatments.